Savings Improve Faster Than Care Quality in New Medical Home Pilot
Five years ago, Capital BlueCross asked community oncology practices in its network what kind of reimbursement model they would like to try as they worked to stay financially viable and independent.
Why Oncology Can Be a Tough Sell in Maine
Chimeric antigen receptor T-cell therapy may soon hit the market, and numerous cancer care centers are poised to offer this for what may be the first FDA-approved indication: relapsed/refractory B-cell acute lymphoblastic leukemia.
Proposed Changes to 340B May Curb Hospital Abuses
Outpatient branded drug sales in the 340B Drug Pricing Program now amount to almost 8% of the total market, well up from 5.4% in 2012.
Artificial Intelligence Is Still a Long Way From Understanding the Subtlety of a Texas Metaphor
It is not far-fetched to believe that, one day soon, automated systems will be able to obtain payer approval for therapies without any human involvement.
What If You Cannot Afford CAR T-Cells?
Despite all the excitement and anticipation, there is a growing anxiety among payers and providers regarding the cost of CAR T cells.
ACCC Seeks to Build a Better Lung Cancer Model
The Association of Community Cancer Centers has long recognized the principle of mass-producing success based on an individual cancer center's achievement.
PROs Save Money, Lives, and Improve QoL
Despite improved outcomes with new treatment and targeted therapies, patients with cancer continue to be afflicted by distressing symptoms and serious toxicities, which affect daily functioning and quality of life.
Arizona Oncology Center Uses State of the Art Facility to Gain Market Share
Architects can tailor new buildings to oncology’s specific needs and Arizona Oncology built its newest facility from the ground up rather than renting generic offices.
Using Population Science to Fill in the Blanks
When it comes to treating older populations for cancer, it’s often the case that the only available data are based on trials of younger patients in far healthier condition.
Dr Phillips on the Treatment Landscape for Patients With MCL
Dr Chari on the Bridging the Gaps in Hematologic Malignancies Meeting
Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL
2 Commerce Drive Cranbury, NJ 08512